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Acute Lymphoblastic Leukaemia (ALL) is a common form of 
blood cancer that usually affects children under 15 years of age. 
Chemotherapy treatment for ALL is delivered in three phases 
viz. induction, intensification, and maintenance. The 
maintenance phase involves oral administration of the 
chemotherapy drug 6-Mercaptopurine (6-MP) in varying doses 
to destroy any remaining abnormal cells and prevent 
reoccurrence. A key side effect of the treatment is a reduction in 
neutrophil counts which can lead to a condition known as 
neutropenia. This carries a risk of secondary infection and has 
been linked to 60% ALL fatalities. Current practice aims to 
control neutrophil counts by varying 6-MP dosages on a weekly 
basis and is based upon clinical judgment and experience of the 
medical professionals involved. Conceived as a decision support 
aid for clinicians then, presented are the results of a machine 
learning technique that predicts neutrophil counts one or more 
weeks ahead using data from ALL blood test results and 6-MP 
dosing. In this work, a model is trained and validated using data 
from a single female ALL patient’s maintenance phase. The 
prediction error is found to be typically within +/- 290/microL at 
one week and within +/- 820/microL for a 14 day prediction. 
 
Index Terms—Leukaemia, Neutrophils, Artificial Neural 
Networks, Time Series Prediction 
I. INTRODUCTION 
Acute Lymphoblastic Leukaemia (ALL) is the most 
common form of cancer in children and represents 80% of 
all leukaemia cases [1]. As the number of children with this 
type of leukaemia grows worldwide so does the demand for 
research into more effective treatment regimens. ALL is a 
form of leukaemia that affects lymphocytes; a type of white 
blood cell. ALL is an overproduction of immature 
lymphocytes called lymphoblast, or blast cells. These cells 
flood the bone marrow and prevent the body from 
producing the correct amounts of healthy cells in order to 
function normally. If untreated, ALL progression is rapid 
and requires aggressive chemotherapy treatment. The 
protocol for treating ALL typically spans 2 years for girls 
and 3 for boys. It consists of three phases of chemotherapy 
treatment viz. induction, intensification and maintenance -
with the latter being the most protracted, lasting around 18 
months for girls and 30 months for boys. 
The induction phase is designed to achieve initial 
remission and involves intravenous administration of 
various drugs including vincristine, methotrexate and 
dexamethasone. Intensification is the most concentrated 
phase of treatment and is aimed at destroying remaining 
abnormal cells. The aim of the maintenance phase is to kill 
any remaining cells left over from the first two phases to 
minimize the chance of relapse. During this phase, patients 
receive doses of the chemotherapy drug 6-mercaptopurine 
(6-MP), typically administered orally on a daily basis [2]. 
6-MP’s effect is to damage the RNA or DNA thereby 
disrupting the natural division process, ultimately resulting 
in cell death. A primary side effect of this treatment, 
however, is a reduction in neutrophil counts which can lead 
to neutropenia (abnormally low level of neutrophils) and so 
presents a risk for acquiring secondary infection. Typically, 
neutropenia results in regular hospitalizations and/or 
unscheduled breaks in the treatment regime. Also, patients 
with neutropenia are at high risk of secondary infections 
with associated fatalities of 60% [3].  
Decreasing drug dosages can reduce the risk of 
neutropenia, but can degrade treatment effectiveness. 
Conversely, increasing drug dosages where appropriate can 
be beneficial but dosing regimens are not always able to 
support such decisions with a satisfactory degree of 
accuracy.  Medical professionals aim to control counts by 
varying 6-MP dosages on a weekly basis. Typically the aim 
is to achieve neutrophil counts between [1,1.5]  ×  109 
neutrophils per liter of blood. Patients with a count smaller 
than 0.5 × 109  are classed as neutropenic, i.e. no effective 
immune system at which point treatment is stopped until 
counts increase above the minimum threshold. Weekly 
blood counts are used to inform weekly dosing decisions 
  
and typically patients are prescribed 100%, 75% or 50% of 
the calculated dose (per kg body mass).     
Hence, the motivation of this work is to explore a 
machine learning technique that can predict, at least one 
week ahead, neutrophil counts. It is hoped that further 
research and development leads to supporting clinical 
decisions of 6-MP dose manipulations to reduce instances 
of neutropenia in children with ALL. 
To the authors’ knowledge, currently there is not wide 
reporting of methods for predicting neutrophil counts using 
a machine learning technique such as that presented herein. 
In the literature, such techniques have shown success when 
applied to other medical conditions. 
An anti-diabetic drug failure prediction methodology for 
type 2 diabetes investigated by Kang, S. et al. [4] using 
support vector machines (SVM) proposed an ensemble of 
SVM for a large scale dataset, reporting a prediction 
accuracy of about 80%. Menden, M.P. et al. [5] also 
proposed a drug prediction methodology using analysis of  
variance (ANOVA) which aimed to predict patient response 
to a specific cancer therapy. Lin, C. et al. [6] carried out an 
investigation in applying neural networks to predict the 
likelihood of patient response to clozapine during the 
treatment of schizophrenia. The research showed that all 
clozapine responders and approximately 75% of non-
responders were successfully predicted by the resulting 
artificial neural network (ANN) model. A similar study into 
the prediction of clozapine response was carried out by 
Khodayari-Rostamabad, A. et al. [7]. Machine learning 
techniques were applied to pre-treatment 
electroencephalography (EEG) data from schizophrenia 
patients in order to predict the likely response to clozapine 
therapy in adults suffering from schizophrenia. These 
techniques were able to predict, in advance of the first dose, 
whether a patient will or will not respond to the powerful 
but potentially toxic medication. The level of performance 
using the leave-one-out validation method was ≈85%. Yuan 
Li et al. [8] have developed a data-driven predictive system 
using machine learning techniques. The framework has 
been validated in vitro though experimental study with 
Giardia lamblia and the system categorizes the set of data 
using Fuzzy c-means clustering algorithm. It used a 
Probabilistic Suffix Automaton (PSA) to model the 
temporal state sequences. The accuracy of the system was 
73% with four data points and 97.5% with nine data points.  
This paper describes a time series prediction technique 
using an artificial neural network to predict future 
neutrophil counts based on measured blood count data and 
6-MP dosing. Compared is the accuracy of the predicted 
neutrophil count with known (i.e. expected) counts.  
II. BACKGROUND 
Time series prediction, used for the current work, is a 
machine learning technique that is commonly used in 
weather forecasting, business planning, economic 
predictions and signal processing. Data from previously 
observed system states are used to create a model to predict 
future states. Although there are a large number of 
algorithms demonstrating high reliability in prediction, 
difficulties can arise when attempting to model systems that 
are highly non-linear, such as in drug prediction.  In other 
fields, ANNs have been shown to provide accurate 
prediction results in such cases [9-12]. They represent a 
group of statistical algorithms inspired by biological neural 
networks that are able to learn system behavior from a 
sufficient number of inputs.  In a biological system, the 
transmission of a signal from one neuron to another, 
through a synapse, releases specific transmitter substances. 
The outcome is to lower or raise the electrical potential 
inside the body of the receiving cell. Once the electrical 
potential reaches a threshold the neuron will fire. It is this 
underlying process that the artificial neuron tries to mimic 
[13], as depicted in Fig. 1 [9] [14]. 
 
 
 
Fig. 1 Artificial Neuron Structure 
The neuron has  𝑥1, 𝑥2, 𝑥𝑗 … 𝑥𝑛  inputs each attributed a 
weight  𝑥1, 𝑥2, 𝑥𝑗 … 𝑥𝑛 . Input weightings are dependent on 
each individual inputs contribution to the output prediction 
and are analogous to the synaptic connections in biological 
neurons. The activation corresponding to the graded 
potential is given by [8], Eq. 1 
    𝑎 = ∑ 𝑤𝑗𝑢𝑗
𝑁
𝑗=0 + 𝜃                               (1) 
where θ represents the threshold in the artificial neuron. 
Typically, the modelling of complex functions is not 
achievable through a single artificial neuron and so layers 
of artificial neurons are formed, where the outputs from 
many neurons are connected as inputs to the others and thus 
building a neural network. When making such a network, 
  
the formula above can be modified by expressing the 
activation 𝑖𝑡ℎ neuron as Eg. 2, 
 
                                  𝑎𝑖 = ∑ 𝑤𝑗𝑖𝑥𝑗
𝑁
𝑗=0 + 𝜃𝑖                       (2) 
where, 𝑥𝑗  is either the output of another neuron or an 
external input. Neural Networks are made up of a number 
of layers, the first being the input layer, the last the output 
layer and all layers between are the hidden layers. Each 
layer also carries a weight determined during the training 
phase. 
In this paper we use Nonlinear AutoRegressive with 
eXogenous inputs of an ANN model (NARX) in Matlab 
2012b. In a NARX network, the output signal of the 
network composes the input vector of the network using 
delay operators. A mathematical formulation of the output 
final response is expressed below:  
𝑦(𝑛 + 1) = 𝑓[𝑦(𝑛), 𝑦(𝑛 − 1), …, 
 𝑦(𝑛 − 𝑑𝑦 + 1);  𝑥(𝑛), 𝑥(𝑛 − 1), …,  
          𝑥(𝑛 − 𝑑𝑥 + 1)] = 𝑓[𝑦(𝑛); 𝑥(𝑛); 𝑊]                (3) 
Where x(n) and y(n) are the components of the input 
and output vector respectively. The delays being 𝑑𝑥 and 𝑑𝑦, 
𝑊  is the matrix of the adjustable weights and 𝑓  is the 
unknown nonlinear function. 
III. METHODOLOGY 
A clinical dataset from the maintenance phase treatment 
of one female ALL patient is used in the current work. Data 
consists of multiple full blood counts and blood 
differentials along with corresponding 6-MP dosages. Table 
I shows the ranges of the data in the medical records used. 
TABLE I. INPUT PARAMETERS 
Input Range 
Days of treatment [1,588] 
Hemoglobin  (g/dL) [78,169] 
White Cell Count (10*9/L) [0.4,11.9] 
Platelets  (10*9/L) [87,507] 
Red Cell Count (10*12/L) [2.03,5.05] 
Mean Cell Volume (fL) [89,104] 
Hematocrit  [0.134,0.496] 
MCH  (pg) [28.9,34.6] 
MCHC  (g/dL) [315,354] 
Lymphocytes  (10*9/L) [0.25,2.83] 
Monocytes  (10*9/L) [0,1.2] 
Eosinophils (10*9/L) [0,0.4] 
Basophils  (10*9/L) [0,0.1] 
6-marcaptopurine (mg) [0,80] 
Neutrophil counts (10*9/L) [0,8.43] 
The measured neutrophil count for the full 588 day 
treatment period is shown in Fig. 2 in which the graph 
markers indicate days when bloods were sampled. 
 
Fig. 2 Neutrophil counts during the Maintenance phase 
To improve the accuracy of prediction, the dataset in 
Table I is first interpolated producing 588 samples over the 
treatment period. Data normalization, Eq. 4, is necessary 
prior to training 
                      ?̅? =
𝑋−𝑋𝑚𝑖𝑛
𝑋𝑚𝑎𝑥−𝑋𝑚𝑖𝑛
                                    (4) 
 
where X is the actual value of the sample and 𝑋𝑚𝑎𝑥  and 
𝑋𝑚𝑖𝑛  are the maximum and minimum values. Figure 3 
shows a graph of the normalized and interpolated dataset.  
 
Fig. 3 Neutrophil counts after normalization and interpolation 
 
The dataset is sub-divided as follows: 70% training, 
30% for validation. Following training, the ANN is used to 
predict the patient neutrophil count one or more weeks 
ahead, and the resulting prediction compared with the 
actual count. The accuracy of two-week and three-week 
ahead predictions are also investigated. This opens the 
possibility of fortnightly blood tests and dosing should 
neutrophil counts be relatively high and if 14 day 
predictions from the ANN be consistently of sufficient 
accuracy. 
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IV. RESULTS AND DISCUSSION 
A. One week ahead neutrophil prediction 
Approximately four months of training data has been 
found to be the minimum threshold for training the NARX 
ANN. Training datasets of this size have been used to 
produce all the results in the following graphs and tables. 
Three different training datasets were created from the 
normalized blood test data in the 4 months preceding days 
113, 233 and 352 and Figs. 4, 5 and 6 graph the predictions 
for the values in the next 7 days. The dashed lines display 
the close fit between the ANN’s prediction of future values 
and the expected (known) values.  
 
Fig. 4 Normalized neutrophil counts. Prediction period: 7 days 
 
Fig. 5 Normalized neutrophil counts. Prediction period: 7 days 
Fig. 6 Normalized neutrophil counts. Prediction period: 7 days 
B. Two weeks ahead neutrophil prediction 
Extending the prediction period to two weeks shows 
some degradation in the quality of the fit but Figs. 7, 8 and 
9 do show qualitatively a reasonable agreement with the 
expected (known) value 14 days ahead. 
  
 
Fig. 7 Normalized neutrophil counts. Prediction period: 14 days 
 
Fig. 8 Normalized neutrophil counts. Prediction period: 14 days  
 
 
Fig. 9 Normalized neutrophil counts. Prediction period: 14 days 
 
When analyzing the results, a reduction in accuracy was 
expected as the time period was increased – predictions of 
the future get more difficult in proportional to the size of 
look-ahead time period. There is also a degree of caution 
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necessary when utilizing a ‘black-box’ function such as 
neural network for prediction. This is illustrated by 
inspecting Fig. 7 and Fig. 8 and comparing with Fig. 9. 
Visible in Fig. 9 is a significant deterioration in the quality 
of the prediction after day 369.  
For a quantitative analysis of the expected error, 10 
unique predictions were made, each of three different time 
periods; 7, 14, and 21 days ahead. Those 30 predictions 
were then compared with measured blood test results - not 
interpolated or normalized data. The standard error was 
found and used to produce a 95% confidence interval (CI), 
Table II and Fig. 10. As expected, the bounds of our likely 
prediction error increase (≈ 2.8 times) in transitioning from 
a 7 to a 14 day prediction. We also judge from this analysis 
the 21 day prediction to be unreliable at the time of writing. 
 
TABLE II. Errors in the ANN time series prediction 
 Normalized 
error 
Error in Neutrophil prediction 
and 95% confidence intervals 
Prediction 
(days ahead) 
10
3
 
MSE 
10
2
 
RMSE 
Lower 
Mean 
(10
9
 / L) 
Upper 
7 2.87 5.36 -0.27 0.00523 0.285 
14 22.5 15.01 -0.74 0.03620 0.812 
21 147.0 38.38 -2.73 -0.88954 0.953 
 
 
Fig. 10 Errors in 1, 2 and 3 week prediction (95% CI as error bars) 
V. CONCLUSION AND FUTURE WORK 
Predicting neutrophil counts with sufficient accuracy a 
week or more ahead is highly desirable. The potential is 
significant: aiding clinicians in reducing the risk of 
neutropenia thereby facilitating improved treatment success 
and reducing the number of Acute Lymphoblastic 
Leukaemia deaths brought about because of secondary 
infections.  
In this paper, a description of an Artificial Neural 
Network tasked with predicting neutrophil count in Acute 
Lymphoblastic Leukaemia prediction has been presented. 
Blood tests results and 6-MP dosages from a 588 day 
treatment period for a female ALL patient were used for the 
training. 
The results show effective prediction 7 days ahead using 
relatively modest training datasets (4 months historic data). 
Prediction accuracy degrades with increasing time period. 
The current work indicates that 21 day ahead predictions 
are not to be relied upon with the current implementation.  
If machine-based learning techniques such as these can 
aid clinicians in decision making, then possibilities of time-
off treatment and time spent in hospital, plus the associate 
costs, are reduced along with the potential from improved 
clinical outcomes for the patient. 
In further work, we intend to improve the algorithm and 
gather more patient datasets to see if this method can be 
generalized with a view to improving its accuracy and 
performance. The authors also recognize that, not only 
could this work stream be significant in terms of enhancing 
the treatment of ALL, but that possibilities exist to extend 
this method for other drug dosing regimens where control is 
required, such as in the treatment of other types of cancer 
and clozapine treatment for schizophrenia. 
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